Saturday, August 01, 2015 3:50:41 PM
Patently BIOtech
Patents are the lifeblood of medical innovation. They are the cornerstone that enables companies to perform the long and costly research and development for cures and therapies to combat devastating diseases such as cancer, HIV and Alzheimer’s.
Unfortunately, the system that helps protect these innovations is being abused by outside interests. BIO and others have called upon Congress to fix these problems as part of a greater patent reform debate.
Today one more voice joined the chorus calling upon Congress to promptly combat these opportunistic “reverse trolls.” Joseph Gulfo, executive director of The Rothman Institute at Fairleigh Dickinson penned an excellent op-ed that ran on CNBC’s website today.
In Mr. Gulfo’s own words:
“Despite hedge funds’ attempt to position these efforts as being in the public’s interest to reduce prices of drugs, this has the tone of stock manipulation, and the pharmaceutical industry has taken notice, calling for stricter standing requirements for IPR petitioners.”
For more information, read this statement on BIO’s opposition H.R. 9, the Innovation Act, or visit Patent Reform For Cures where you can contact your elected representatives to register your concern.
http://www.biotech-now.org/public-policy/patently-biotech/2015/07/cnbc-commentary-hedge-funds-reverse-trolls-crushing-biopharma-innovation?utm_source=Feedburner&utm_medium=feed&utm_campaign=Feed%3A+BiotechNow+%28BIOtech+Now%29&utm_term=RSS+Subscription
Recent CSCI News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/23/2024 11:30:23 AM
- COSCIENS Biopharma Inc. Provides Updates on Merger Integration, Management Succession Plans and Ongoing Development Programs • GlobeNewswire Inc. • 09/23/2024 11:30:00 AM
- Form SC 13D - General Statement of Acquisition of Beneficial Ownership • Edgar (US Regulatory) • 09/06/2024 06:04:41 PM
- COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency • GlobeNewswire Inc. • 08/27/2024 11:30:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/13/2024 12:05:36 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/13/2024 12:05:17 PM
- COSCIENS Biopharma Inc. Reports Second Quarter 2024 Financial Results • GlobeNewswire Inc. • 08/13/2024 12:05:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM